Trade Show

Meet Datwyler at
Pharmapack

Connecting with the Global Packaging Community — and Taking the Stage on the Future of Subcutaneous Self-Delivery

Datwyler joined the global pharmaceutical packaging community at Pharmapack 2026 in Paris, showcasing container closure systems and drug delivery innovations for biologics and injectable applications. Missed our presentation on the evolution of self-delivery solutions for subcutaneous administration? Watch it on-demand now.

Date January 21, 2026 – January 22, 2026

Location Paris Expo Porte de Versailles | Paris, France

Details Booth #4D21

Watch Presentation View Event Details

Event Overview

Where Subcutaneous Innovation Meets the Global Packaging Community

Datwyler joined the global pharmaceutical packaging community at Pharmapack 2026 in Paris, showcasing container closure systems, elastomer innovations, and drug delivery components engineered for biologics, injectables, and patient-centric applications. Missed our presentation? Watch it on-demand now. In "When Size Matters: Evolution of Self-Delivery Solutions for Subcutaneous Administration," Paolo Ferrigno, Product Manager, Prefilled Syringes and Cartridges at Datwyler, joined Valerio Ravazzolo, Product Manager, Cartridge Platform at Stevanato Group, and Greg Moakes, EVP, New Business Development at LTS Device Technologies, for a collaborative deep-dive into the challenges of large-volume subcutaneous delivery and how container closure system platform solutions are evolving to meet them.

Featured Presentations

Presentation Details

When Size Matters: Evolution of Self-Delivery Solutions for Subcutaneous Administration

Date & Time January 22, 2026 • 12:50 PM

Location Pharmapack Learning Labs: 4A89

As biologics grow more complex and self-administration volumes push well beyond traditional limits, the question is no longer whether large-volume subcutaneous delivery is possible — it's how fast the industry can make it a reality. In "When Size Matters: Evolution of Self-Delivery Solutions for Subcutaneous Administration," Paolo Ferrigno of Datwyler, Valerio Ravazzolo of Stevanato Group, and Greg Moakes of LTS Device Technologies present a compelling case for pre-verified, platform-based collaboration as the fastest path to market for large-volume SC delivery systems. Drawing on preliminary functional testing data across 5 mL, 10 mL, and 20 mL cartridge configurations — including break-loose force, gliding force, dose accuracy, delivery time, and hold-up volume results — the presentation demonstrates that accurate, self-administered subcutaneous delivery up to 20 mL is not only achievable, but achievable with the performance and patient-centric specifications modern on-body injectors demand. The key? A reliable ecosystem of pre-verified drug delivery components developed through open, structured collaboration among suppliers before the pharmaceutical company ever enters the picture.

View Paolo Ferrigno View Valerio Ravazzolo View Greg Moakes

Speaker Spotlight

Meet the Speakers

Paolo Ferrigno

Product Manager, Prefilled Syringes & Cartridges | Datwyler

In the industry of primary parenteral packaging since 2017, Paolo Ferrigno is currently the Product Manager for PFS and cartridge components at Datwyler Healthcare. In the same company, Paolo covered different commercial and technical toles before landing back to product management in 2022. Educated in Electronics and later in Marketing, Paolo had in the past a wide range of experiences spanning from R&D for audio/electronics in the automotive and consumer markets to product management for B2B distribution of industrial and electronics components.

View LinkedIn

Valerio Ravazzolo

Product Manager, Cartridge Platform | Stevanato Group

Valerio Ravazzolo is Product Manager for the Cartridge Platform within the DCS Business Unit at Stevanato Group, where he focuses on the evolution of cartridge solutions from both a technical and market perspective.

He joined Stevanato Group in 2015, starting in Quality Assurance and later moving into a Technical Account Manager role. In this position, he supported key customers and gradually expanded his scope of responsibility.

Today, as Product Manager, he brings together this experience to support product strategy, development, and long‑term platform growth.

Valerio holds a master's degree in mechanical engineering from the University of Padua.

View LinkedIn

Greg Moakes

Executive VP, New Business Development | LTS Device Technologies

Greg Moakes is Executive Vice-President of Business Development for LTS Lohmann Device Technologies. Dr Moakes holds a PhD in Chemistry from the Georgia Institute of Technology (Atlanta, GA, US) and an MBA from the Southern Methodist University (Dallas, TX, US). His career had been focused on drug delivery, first specialising in solid-implant dosage formulations and more recently high-volume subcutaneous delivery via on-body delivery systems.

View LinkedIn

Solutions Spotlight

What We're Showcasing at Pharmapack

Explore the solutions and technologies most relevant to this event.

Featured Solution

In Case You Missed It: Watch the Presentation On-Demand

Datwyler's Paolo Ferrigno joined Valerio Ravazzolo of Stevanato Group and Greg Moakes of LTS Device Technologies for a collaborative presentation — "When Size Matters: Evolution of Self-Delivery Solutions for Subcutaneous Administration" — addressing large-volume subcutaneous delivery challenges and how container closure system platform solutions are evolving to meet them. Watch it on-demand now.

Featured Solution

The NeoFlex™ Plunger Platform for Large-Volume Injectables

Datwyler's NeoFlex™ plunger — the first-to-market 20ml universal plunger — was engineered to support the growing demand for large-volume injectable therapies, offering compatibility across multiple prefilled syringe and cartridge platforms, simplified development, and reduced qualification complexity for biologic and high-dose therapies.

Featured Solution

Drug Delivery Solutions for Home-Based & Patient-Centric Care

As subcutaneous and at-home administration redefines the standard of care, Datwyler showcased reliable components compatible with biologics and GLP-1 formulations, including solutions for auto-injectors, prefillable syringe systems, and ready-to-use components designed for contamination-free fill-finish operations.

Additional Information